Tilray Brands Reports $218 Million Q2 Revenue, Market Reacts Positively
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 11h ago
0mins
Source: Fool
- Revenue Growth: Tilray reported $218 million in revenue for Q2 of fiscal 2026, marking a record for the quarter and surpassing analyst expectations, although the year-over-year growth was only 3%, indicating cautious optimism from the market regarding its future.
- Net Loss Reduction: Despite a decline in gross margin from 29% to 26%, Tilray narrowed its net loss to $43.5 million compared to $85.3 million in the prior year, suggesting some progress in cost control measures.
- Market Opportunity: Following President Trump's executive order reclassifying cannabis as a Schedule 3 substance, Tilray plans to expand its medical cannabis operations in the U.S. with the launch of Tilray Medical USA, aiming to broaden its product portfolio and reach a wider patient base through partnerships in the medical field.
- Competitive Pressure: While Tilray faces a larger market opportunity, the increasing competition from well-established multistate operators in the U.S. necessitates that Tilray develops a competitive advantage to maintain its market share, leaving its future profitability in question.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 9.455
Low
8.50
Averages
9.57
High
10.00
Current: 9.455
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
